Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old

Paul Zarogoulidis, Haidong Huang, Chong Bai, Dimitris Petridis, Susana Papadopoulou, Eleni Faniadou, Ellada Eleftheriadou, Georgia Trakada, Kosmidis Cristoforos, Aggeliki Rapti, Lonny Yarmus, David Feller-Kopman, Yan Gao Man, Wolfgang Hohenforst-Schmidt

Research output: Contribution to journalArticle

Abstract

Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patients that received only best supportive care. Results: The median life of patients at the date of disease progression, although increased by the administration of the drug (92 days versus 70) was not confirmed statistically significantly (Mann-Whitney test: W = 280, p = 0.138). The administration of drug seems to keep stable the biological condition of patients (McNemar's test: X2 = 0.033, p = 0.99). Patients with chemotherapy the death rate was increased by 50% as compared to those with best supportive care (12 vs 8), the median life until the unfortunate event surpassed statistically significantly the latter (150 days of life as compared to 108, Mann-Whitney test: W = 57.5, p = 0.045). Discussion: Nab-paclitaxel as a monotherapy could be considered as a first line treatment option for patients > 75 years of age without any previous cardiological medical history when compared to best supportive care.

Original languageEnglish (US)
Pages (from-to)1673-1678
Number of pages6
JournalJournal of Cancer
Volume8
Issue number9
DOIs
StatePublished - 2017

Fingerprint

Therapeutics
130-nm albumin-bound paclitaxel
Pharmaceutical Preparations
Disease Progression
Lung Neoplasms
Neoplasms
Drug Therapy
Mortality

Keywords

  • Abraxane
  • Adenocarcinoma
  • Chemotherapy
  • Nab-paclitaxel
  • NSCLC
  • Squamus

ASJC Scopus subject areas

  • Oncology

Cite this

Zarogoulidis, P., Huang, H., Bai, C., Petridis, D., Papadopoulou, S., Faniadou, E., ... Hohenforst-Schmidt, W. (2017). Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old. Journal of Cancer, 8(9), 1673-1678. https://doi.org/10.7150/jca.19463

Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old. / Zarogoulidis, Paul; Huang, Haidong; Bai, Chong; Petridis, Dimitris; Papadopoulou, Susana; Faniadou, Eleni; Eleftheriadou, Ellada; Trakada, Georgia; Cristoforos, Kosmidis; Rapti, Aggeliki; Yarmus, Lonny; Feller-Kopman, David; Man, Yan Gao; Hohenforst-Schmidt, Wolfgang.

In: Journal of Cancer, Vol. 8, No. 9, 2017, p. 1673-1678.

Research output: Contribution to journalArticle

Zarogoulidis, P, Huang, H, Bai, C, Petridis, D, Papadopoulou, S, Faniadou, E, Eleftheriadou, E, Trakada, G, Cristoforos, K, Rapti, A, Yarmus, L, Feller-Kopman, D, Man, YG & Hohenforst-Schmidt, W 2017, 'Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old', Journal of Cancer, vol. 8, no. 9, pp. 1673-1678. https://doi.org/10.7150/jca.19463
Zarogoulidis P, Huang H, Bai C, Petridis D, Papadopoulou S, Faniadou E et al. Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old. Journal of Cancer. 2017;8(9):1673-1678. https://doi.org/10.7150/jca.19463
Zarogoulidis, Paul ; Huang, Haidong ; Bai, Chong ; Petridis, Dimitris ; Papadopoulou, Susana ; Faniadou, Eleni ; Eleftheriadou, Ellada ; Trakada, Georgia ; Cristoforos, Kosmidis ; Rapti, Aggeliki ; Yarmus, Lonny ; Feller-Kopman, David ; Man, Yan Gao ; Hohenforst-Schmidt, Wolfgang. / Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old. In: Journal of Cancer. 2017 ; Vol. 8, No. 9. pp. 1673-1678.
@article{91c0c4b3019a46c5ba82017bd5c5ad79,
title = "Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old",
abstract = "Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patients that received only best supportive care. Results: The median life of patients at the date of disease progression, although increased by the administration of the drug (92 days versus 70) was not confirmed statistically significantly (Mann-Whitney test: W = 280, p = 0.138). The administration of drug seems to keep stable the biological condition of patients (McNemar's test: X2 = 0.033, p = 0.99). Patients with chemotherapy the death rate was increased by 50{\%} as compared to those with best supportive care (12 vs 8), the median life until the unfortunate event surpassed statistically significantly the latter (150 days of life as compared to 108, Mann-Whitney test: W = 57.5, p = 0.045). Discussion: Nab-paclitaxel as a monotherapy could be considered as a first line treatment option for patients > 75 years of age without any previous cardiological medical history when compared to best supportive care.",
keywords = "Abraxane, Adenocarcinoma, Chemotherapy, Nab-paclitaxel, NSCLC, Squamus",
author = "Paul Zarogoulidis and Haidong Huang and Chong Bai and Dimitris Petridis and Susana Papadopoulou and Eleni Faniadou and Ellada Eleftheriadou and Georgia Trakada and Kosmidis Cristoforos and Aggeliki Rapti and Lonny Yarmus and David Feller-Kopman and Man, {Yan Gao} and Wolfgang Hohenforst-Schmidt",
year = "2017",
doi = "10.7150/jca.19463",
language = "English (US)",
volume = "8",
pages = "1673--1678",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "9",

}

TY - JOUR

T1 - Nab-paclitaxel as first line treatment for NSCLC in elderly patients more than 75 years old

AU - Zarogoulidis, Paul

AU - Huang, Haidong

AU - Bai, Chong

AU - Petridis, Dimitris

AU - Papadopoulou, Susana

AU - Faniadou, Eleni

AU - Eleftheriadou, Ellada

AU - Trakada, Georgia

AU - Cristoforos, Kosmidis

AU - Rapti, Aggeliki

AU - Yarmus, Lonny

AU - Feller-Kopman, David

AU - Man, Yan Gao

AU - Hohenforst-Schmidt, Wolfgang

PY - 2017

Y1 - 2017

N2 - Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patients that received only best supportive care. Results: The median life of patients at the date of disease progression, although increased by the administration of the drug (92 days versus 70) was not confirmed statistically significantly (Mann-Whitney test: W = 280, p = 0.138). The administration of drug seems to keep stable the biological condition of patients (McNemar's test: X2 = 0.033, p = 0.99). Patients with chemotherapy the death rate was increased by 50% as compared to those with best supportive care (12 vs 8), the median life until the unfortunate event surpassed statistically significantly the latter (150 days of life as compared to 108, Mann-Whitney test: W = 57.5, p = 0.045). Discussion: Nab-paclitaxel as a monotherapy could be considered as a first line treatment option for patients > 75 years of age without any previous cardiological medical history when compared to best supportive care.

AB - Lung cancer is still the leading cause of cancer among cancer patients. Although there are novel therapies as second line treatment for NSCLC, there is an issue for elderly patients. Patients and Methods: We collected retrospectively data from 60 patients >75 years of age. Thirty of these patients received nab-paclitaxel and first line treatment and were compared to thirty patients that received only best supportive care. Results: The median life of patients at the date of disease progression, although increased by the administration of the drug (92 days versus 70) was not confirmed statistically significantly (Mann-Whitney test: W = 280, p = 0.138). The administration of drug seems to keep stable the biological condition of patients (McNemar's test: X2 = 0.033, p = 0.99). Patients with chemotherapy the death rate was increased by 50% as compared to those with best supportive care (12 vs 8), the median life until the unfortunate event surpassed statistically significantly the latter (150 days of life as compared to 108, Mann-Whitney test: W = 57.5, p = 0.045). Discussion: Nab-paclitaxel as a monotherapy could be considered as a first line treatment option for patients > 75 years of age without any previous cardiological medical history when compared to best supportive care.

KW - Abraxane

KW - Adenocarcinoma

KW - Chemotherapy

KW - Nab-paclitaxel

KW - NSCLC

KW - Squamus

UR - http://www.scopus.com/inward/record.url?scp=85021235438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021235438&partnerID=8YFLogxK

U2 - 10.7150/jca.19463

DO - 10.7150/jca.19463

M3 - Article

C2 - 28775787

AN - SCOPUS:85021235438

VL - 8

SP - 1673

EP - 1678

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 9

ER -